About us
Stephen Anthony, DO
CMO
Over 20 years of clinical practice in both private and academic settings as a hematologist-oncologist, possess extensive knowledge and experience in Pre-IND and IND of New Chemical Entities (NCEs) and all stages of clinical trials
Currently leading clinical studies of LP-108, LP-118 and LP-168 in the US and Europe